Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

CRISPR Developer Awarded Lemelson-MIT Prize

By Lemelson-MIT | September 21, 2017

Dr. Feng Zhang, a pioneer of the revolutionary CRISPR gene editing technology, TAL effectors, and optogenics, has just been announced as the recipient of the 2017 $500,000 Lemelson-MIT Prize, the largest cash prize for invention in the United States. Zhang is a core member of the Broad Institute of MIT and Harvard, an investigator at the McGovern Institute for Brain Research, James and Patricia Poitras Professor in Neuroscience at MIT, and associate professor in the departments of Brain and Cognitive Sciences and Biological Engineering at MIT.

Zhang and his team were first to develop and demonstrate successful methods for using an engineered CRISPR-Cas9 system to edit genomes in living mouse and human cells and have turned CRISPR technology into a practical and shareable collection of tools for robust gene editing and epigenomic manipulation.  CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, has been harnessed by Zhang and his team as a groundbreaking gene-editing tool that is simple and versatile to use. A key tenet of Zhang’s is to encourage further development and research through open sharing of tools and scientific collaboration. Zhang believes that wide use of CRISPR-based tools will further our understanding of biology, allowing scientists to identify genetic differences that contribute to diseases and, eventually, provide the basis for new therapeutic techniques.

Zhang’s lab has trained thousands of researchers to use CRISPR technology and since 2013 he has shared over 40,000 plasmid samples with labs around the world both directly and through the nonprofit Addgene, enabling wide use of his CRISPR tools in their research.

Zhang began working in a gene therapy laboratory at the age of 16 and has played key roles in the development of multiple technologies. Prior to harnessing CRISPR-Cas9, Zhang engineered microbial TAL effectors (TALEs) for use in mammalian cells, working with colleagues at Harvard, authoring multiple publications on the subject and becoming a co-inventor on several patents on TALE-based technologies. Zhang was also a key member of the team at Stanford that harnessed microbial opsins for developing optogenetics, which uses light signals and light-sensitive proteins to monitor and control activity in brain cells. This technology can help scientists understand how cells in the brain affect mental and neurological illnesses. Zhang has co-authored multiple publications on optogenetics and is a co-inventor on several patents related to this technology.

Zhang’s numerous scientific discoveries and inventions, as well as his commitment to mentorship and collaboration, earned him the Lemelson-MIT Prize, which honors outstanding mid-career inventors who improve the world through technological invention and demonstrate a commitment to mentorship in science, technology, engineering and mathematics (STEM).

“Feng’s creativity and dedication to problem-solving impressed us,” said Stephanie Couch, executive director of the Lemelson-MIT Program. “Beyond the breadth of his own accomplishments, Feng and his lab have also helped thousands of scientists across the world access the new technology to advance their own scientific discoveries.”

“It is a tremendous honor to receive the Lemelson-MIT Prize and to join the company of so many incredibly impactful inventors who have won this prize in years past.” said Feng Zhang. “Invention has always been a part of my life – I think about new problems every day and work to solve them creatively. This prize is a testament to the passionate work of my team and the support of my family, teachers, colleagues and counterparts around the world.”

The $500,000 prize, which bears no restrictions in how it can be used, is made possible through the support of The Lemelson Foundation, the world’s leading funder of invention in service of social and economic change.

“We are thrilled to honor Dr. Zhang, who we commend for his advancements in genetics, and more importantly, his willingness to share his discoveries to advance the work of others around the world,” said Dorothy Lemelson, chair of The Lemelson Foundation. “Zhang’s work is inspiring a new generation of inventors to tackle the biggest problems of our time.”

Zhang will speak at EmTech MIT, the annual conference on emerging technologies hosted by MIT Technology Review at the MIT Media Lab on Tuesday, November 7, 2017.

Nominations for 2018 $500,000 Lemelson-MIT Prize

The Lemelson-MIT Program is now seeking nominations for the 2018 $500,000 Lemelson-MIT Prize. Please contact the Lemelson-MIT Program at awards-lemelson@mit.edu for more information or go to: https://lemelson.mit.edu/prize.

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE